Business & Finance
Camurus reports strong Q1 demand for Buvidal
2 April 2020 -

Swedish biopharmaceutical company Camurus AB (STO:CAMX) on Thursday reported continued revenue growth due to strong demand for weekly and monthly Buvidal for treating opioid dependence across markets in the European Union and Australia.

The company plans to release its first quarter results on 7 May 2020.

For 2020, the company's guidance was reiterated with expected product sales and total revenues at the higher end of the prior guidance. Buvidal is currently launched in seven countries in the EU and Australia.

Camurus also said that the Buvidal supply chain has been largely unaffected by the current situation with COVID-19 and measures have been implemented by the company to meet increasing demand and secure product supply to clinics and patients.

Buvidal (buprenorphine prolonged-release solution for subcutaneous injection in prefilled syringe) is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Buvidal is designed for flexible dosing and is available in four weekly strengths (8 mg, 16 mg, 24 mg and 32 mg) and three monthly strengths (64 mg, 96 mg and 128 mg).